A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53

QR Code

A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53

Saved in:

Bibliographic Details
Main Authors:	Congcong Cao, Lin Yao, Aolin Li, Quan Zhang, Zhenan Zhang, Xiaofei Wang, Ying Gan, Yuchen Liu, Qian Zhang
Format:	article
Language:	EN
Published:	Wiley 2021
Subjects:	Medicine (General) R5-920
Online Access:	https://doaj.org/article/9664ba87b76a4ed9ba8fa2ebee558d7d
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Transcriptome-Wide Map of N6-Methyladenosine Methylome Profiling in Human Bladder Cancer
by: Aolin Li, et al.
Published: (2021)

A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer.
by: Yann Neuzillet, et al.
Published: (2012)

TP53 in Myelodysplastic Syndromes
by: Yan Jiang, et al.
Published: (2021)

Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.
by: Elisabeth Silden, et al.
Published: (2013)

CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites
by: Rajeswari Jayavaradhan, et al.
Published: (2019)

Comprehensive Identification of Deleterious <i>TP53</i> Missense VUS Variants Based on Their Impact on TP53 Structural Stability
by: Benjamin Tam, et al.
Published: (2021)

<i>TP53</i> Combined Phenotype Score Is Associated with the Clinical Outcome of <i>TP53</i>-Mutated Myelodysplastic Syndromes
by: Mariko Yabe, et al.
Published: (2021)

TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer
by: Ziwen Zhang, et al.
Published: (2021)

DOR/Tp53inp2 and Tp53inp1 constitute a metazoan gene family encoding dual regulators of autophagy and transcription.
by: Ana Sancho, et al.
Published: (2012)

CRISPR/Cas Technologies and Their Applications in Escherichia coli
by: Huina Dong, et al.
Published: (2021)

Transcriptional repression of GIF1 by the KIX-PPD-MYC repressor complex controls seed size in Arabidopsis
by: Zupei Liu, et al.
Published: (2020)

Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.
by: Carolina Cavaliéri Gomes, et al.
Published: (2012)

Association between the rs1042522 polymorphism in TP53 and prostate cancer risk: An updated meta-analysis
by: Song Fan, et al.
Published: (2017)

Structural insights into DNA cleavage activation of CRISPR-Cas9 system
by: Cong Huai, et al.
Published: (2017)

CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice
by: Yongzhen Liu, et al.
Published: (2017)

Cross-talk between Myc and p53 in B-cell lymphomas
by: Li Yu, et al.
Published: (2019)

Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development
by: Zhen-Dong Xiao, et al.
Published: (2017)

TP53 isoform junction reads based analysis in malignant and normal contexts
by: Suleyman Vural, et al.
Published: (2021)

TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells
by: Selvakumar Anbalagan, et al.
Published: (2021)

Specific mutation screening of TP53 gene by low-density DNA microarray
by: Ang&eacute;lica Rangel-L&oacute;pez, et al.
Published: (2009)

Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression
by: Yubin Guo, et al.
Published: (2020)

Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
by: Kok Gan Chan, et al.
Published: (2021)

Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant
by: Qipan Deng, et al.
Published: (2019)

Definition of CRISPR Cas12a Trans-Cleavage Units to Facilitate CRISPR Diagnostics
by: Hailong Lv, et al.
Published: (2021)

Polimorfismo Pro 72Arg del gen TP53 y enfermedad coronaria
by: Pizarro,Marcela, et al.
Published: (2009)

Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.
by: Amaia Vilas-Zornoza, et al.
Published: (2011)

Comprehensive assessment of TP53 loss of function using multiple combinatorial mutagenesis libraries
by: Vincent Carbonnier, et al.
Published: (2020)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
by: Isabel Grote, et al.
Published: (2021)

Gaining insights into relevance across cancers based on mutation features of TP53 gene
by: Yue Mei, et al.
Published: (2021)

Bacterial resistance to CRISPR-Cas antimicrobials
by: Ruben V. Uribe, et al.
Published: (2021)

Applications of CRISPR-Cas Technologies to Proteomics
by: Georgii Dolgalev, et al.
Published: (2021)

CRISPR/Cas9 in Gastrointestinal Malignancies
by: André Jefremow, et al.
Published: (2021)

c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis
by: Yu Chen Feng, et al.
Published: (2020)

CRISPR-Associated Primase-Polymerases are implicated in prokaryotic CRISPR-Cas adaptation
by: Katerina Zabrady, et al.
Published: (2021)

MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation
by: Anton Shostak, et al.
Published: (2016)

Low-frequency variation in TP53 has large effects on head circumference and intracranial volume
by: Simon Haworth, et al.
Published: (2019)

Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
by: Burair A. Alsaihati, et al.
Published: (2021)

Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
by: Juliana Giacomazzi, et al.
Published: (2014)

The Role of <i>TP53</i> in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors
by: Dennis M. Timmerman, et al.
Published: (2021)

A functionally significant SNP in TP53 and breast cancer risk in African-American women
by: Maureen E. Murphy, et al.
Published: (2017)